New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2013
08:34 EDTPCYCPharmacyclics pullback a buying opportunity, says Credit Suisse
Credit Suisse would use the pullback in Pharmacyclics as a buying opportunity given the multi-billion dollar potential of ibrutinib. Shares are Outperform rated with a $90 price target.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PCYC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use